Cotinga Pharmaceuticals Book/Share
What is the Book/Share of Cotinga Pharmaceuticals?
The Book/Share of Cotinga Pharmaceuticals, Inc. is -0.18
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on TSXV compared to Cotinga Pharmaceuticals
What does Cotinga Pharmaceuticals do?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Companies with book/share similar to Cotinga Pharmaceuticals
- Alpha MOS SA has Book/Share of -0.18
- China Bozza Development has Book/Share of -0.18
- ImaginOn has Book/Share of -0.18
- Canxgold Mining Corp has Book/Share of -0.18
- Smart Employee Benefits has Book/Share of -0.18
- Aton Resources has Book/Share of -0.18
- Cotinga Pharmaceuticals has Book/Share of -0.18
- Pixium Vision SA has Book/Share of -0.18
- Atlantic Avenue Acquisition Corp has Book/Share of -0.18
- Navya SA has Book/Share of -0.18
- LightJump Acquisition has Book/Share of -0.18
- MedMen Enterprises has Book/Share of -0.18
- Global Bio-chem Technology has Book/Share of -0.17